Education
About Us
Working with TipRanks
Follow Us
Agilon Health (AGL)
NYSE:AGL
AGL Analyst Ratings
Hold
5 Buy
11 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AGL Stock 12 Month Forecast
Average Price Target
$4.28
▲(12.04% Upside)
| Highest Price Target$8.50 | Average Price Target$4.28 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
Reiterated
04/17/25
Bernstein
Reiterated
04/17/25
Robert W. Baird
Reiterated
04/15/25
TD Cowen
Reiterated
04/15/25
Wells Fargo
Reiterated
04/07/25
Needham
Reiterated
03/21/25
Bank of America Securities
Reiterated
02/27/25
Benchmark Co.
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
Stifel Nicolaus
$2→$3
Hold
-21.47%
Downside
Reiterated
02/26/25
Agilon Health price target raised to $3 from $2 at StifelAgilon Health price target raised to $3 from $2 at Stifel
William Blair
―
Hold
―
Reiterated
02/26/25
William Blair Remains a Hold on Agilon Health (AGL)We remain encouraged with the initiatives that management is implementing in order to conserve cash and drive stronger operating performance and visibility going forward. However, 2024 full-year results were a significant disappointment versus investor expectations, with management originally predicting $50 million in adjusted EBITDA (at the midpoint of initial guidance) only to end the year with a $154 million loss.
Jefferies
$3.75
Hold
-1.83%
Downside
Reiterated
02/26/25
We give credit for some improvement in that dynamic in '26 after a bullish MA advanced notice (5% Rev/Gross Cost trend, +$25MM Op Inits., 40bps repricing tailwind), but still see EBITDA breakeven slipping to FY27 at this point. Sentiment & Signs of "Light at the PT to $3.75. We acknowledge improving MA sentiment (even w/ recent UNH headlines) & views to a pot'l positive path forward in FY27+ but still want to see more execution to that end. Stay Hold, PT to $3.75, 30x FY27 EV/EBITDA of $38MM.
Leerink Partners
$2.5→$3.5
Hold
-8.38%
Downside
Reiterated
02/26/25
Cautious Hold Rating on Agilon Health Amid Uncertainty and Cost Challenges
Evercore ISI
$3
Hold
-21.47%
Downside
Reiterated
02/26/25
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL), AN2 Therapeutics, Inc. (NASDAQ: ANTX) and Alcon (NYSE: ALC)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
Reiterated
04/17/25
Bernstein
Reiterated
04/17/25
Robert W. Baird
Reiterated
04/15/25
TD Cowen
Reiterated
04/15/25
Wells Fargo
Reiterated
04/07/25
Needham
Reiterated
03/21/25
Bank of America Securities
Reiterated
02/27/25
Benchmark Co.
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
Stifel Nicolaus
$2→$3
Hold
-21.47%
Downside
Reiterated
02/26/25
Agilon Health price target raised to $3 from $2 at StifelAgilon Health price target raised to $3 from $2 at Stifel
William Blair
―
Hold
―
Reiterated
02/26/25
William Blair Remains a Hold on Agilon Health (AGL)We remain encouraged with the initiatives that management is implementing in order to conserve cash and drive stronger operating performance and visibility going forward. However, 2024 full-year results were a significant disappointment versus investor expectations, with management originally predicting $50 million in adjusted EBITDA (at the midpoint of initial guidance) only to end the year with a $154 million loss.
Jefferies
$3.75
Hold
-1.83%
Downside
Reiterated
02/26/25
We give credit for some improvement in that dynamic in '26 after a bullish MA advanced notice (5% Rev/Gross Cost trend, +$25MM Op Inits., 40bps repricing tailwind), but still see EBITDA breakeven slipping to FY27 at this point. Sentiment & Signs of "Light at the PT to $3.75. We acknowledge improving MA sentiment (even w/ recent UNH headlines) & views to a pot'l positive path forward in FY27+ but still want to see more execution to that end. Stay Hold, PT to $3.75, 30x FY27 EV/EBITDA of $38MM.
Leerink Partners
$2.5→$3.5
Hold
-8.38%
Downside
Reiterated
02/26/25
Cautious Hold Rating on Agilon Health Amid Uncertainty and Cost Challenges
Evercore ISI
$3
Hold
-21.47%
Downside
Reiterated
02/26/25
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL), AN2 Therapeutics, Inc. (NASDAQ: ANTX) and Alcon (NYSE: ALC)
Best Analysts Covering Agilon Health
Which Analyst Should I Follow If I Want to Buy AGL and Sell After:
1 Month
xxx
Success Rate
9/20 ratings generated profit
Average Return
+1.62%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.00% of your transactions generating a profit, with an average return of +1.62% per trade.
3 Months
xxx
Success Rate
6/14 ratings generated profit
Average Return
+0.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +0.72% per trade.
1 Year
Success Rate
3/14 ratings generated profit
Average Return
-26.99%
reiterated a buy rating 2 months ago
Copying Sean Dodge's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -26.99% per trade.
2 Years
xxx
Success Rate
3/14 ratings generated profit
Average Return
-36.19%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.43% of your transactions generating a profit, with an average return of -36.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AGL Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
3
4
1
1
2
Buy
0
1
4
5
6
Hold
14
17
19
17
16
Sell
5
3
2
2
2
Strong Sell
0
0
0
0
0
total
22
25
26
25
26
Each month's total comprises the sum of three months' worth of ratings.
AGL Financial Forecast
AGL Stock Forecast FAQ
What is AGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilon Health’s 12-month average price target is 4.28.
What is AGL’s upside potential, based on the analysts’ average price target?
Agilon Health has 12.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AGL a Buy, Sell or Hold?
Agilon Health has a consensus rating of Hold which is based on 5 buy ratings, 11 hold ratings and 2 sell ratings.
What is Agilon Health’s price target?
The average price target for Agilon Health is 4.28. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.50 ,the lowest forecast is $2.00. The average price target represents 12.04% Increase from the current price of $3.82.
The highest analyst price target is $8.50 ,the lowest forecast is $2.00. The average price target represents 12.04% Increase from the current price of $3.82.
What do analysts say about Agilon Health?
Agilon Health’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of AGL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.